Predictive biomarkers for CTLA-4 blockade therapy and for PD-1 blockade therapy

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9863935
SERIAL NO

14399669

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Biomarkers are described for predicting the efficacy, risk of relapse, risk of an immune related adverse event (irAE), or combination thereof for a CTLA-4 blockade treatment, such as ipilimumab, in a subject with melanoma. Biomarkers are also described for predicting the efficacy and clinical benefit for a PD-1 blockade treatment, such as a PD-1 blocking antibody, in a subject with melanoma.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC12902 MAGNOLIA DRIVE TAMPA FL 33612

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Wang, Wenshi Tampa, US 18 8
Weber, Jeffrey S Tampa, US 9 228
Yu, Bin Tampa, US 738 19031

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 9, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 9, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00